🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,063 results for “BRIGHT MINDS BIOSCIENCES INC.” Clear

  1. Nicotine polacrilex

    BRIGHT MINDS BIOSCIENCES INC.

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  2. Nicotine saline infusion 0.00mcg/kg/s

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 1 small molecule completed

    1 trial

  3. Nicotrol

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 1 small molecule completed

    1 trial

  4. Nifedipine 60 MG Extended Release Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. OROS-MPH

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 1 small molecule completed

    1 trial

  6. Omnitram

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule completed

    1 trial

  7. Opioid Agonist

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 1 small molecule completed

    1 trial

  8. Oral methylphenidate and Oral haloperidol

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 1 small molecule completed

    1 trial

  9. Original formulation EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  10. Oshadi Oral Insulin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes

    phase 1 small molecule completed

    1 trial

  11. Outpatient MST/OPTION-A

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 1 other completed

    1 trial

  12. Oxcarbazepine (brand name vs generic drugs)

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  13. OxyCODONE 5 mg Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule active

    1 trial

  14. Oxycodone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule completed

    1 trial

  15. Oxycodone IN

    BRIGHT MINDS BIOSCIENCES INC.

    Physiologically Based Pharmacokinetic

    phase 1 small molecule completed

    1 trial

  16. Oxycodone Medication First

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Drug Abuse (Not Dependent)

    phase 1 small molecule completed

    1 trial

  17. Oxycodone and Midazolam

    BRIGHT MINDS BIOSCIENCES INC.

    Hypercapnia

    phase 1 small molecule completed

    1 trial

  18. PA-824 1000 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  19. PA-824 200mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  20. PF614 solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  21. PRO 2000/5 Gel (P)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 1 small molecule completed

    1 trial

  22. Panobinostat (LBH589), Carboplatin and Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  23. Parotid Gland

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 other completed

    1 trial

  24. Part 1: Cream

    BRIGHT MINDS BIOSCIENCES INC.

    Systemic Exposure to Sunscreen Ingredients

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources